Zacks
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue?
📈
AI Sentiment
Highly Positive
8/10
- Home
- INCY
INCY
Incyte Corp.
as of 12-03-2025 2:32pm EST
$101.24
$0.20
-0.20%
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Chart Type:
Time Range:
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 17.0B | IPO Year: | 1993 |
| Target Price: | $90.71 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.90 | EPS Growth: | 3878.02 |
| 52 Week Low/High: | $53.56 - $109.28 | Next Earning Date: | 10-28-2025 |
| Revenue: | $4,813,105,000 | Revenue Growth: | 18.09% |
| Revenue Growth (this year): | 19.33% | Revenue Growth (next year): | 10.47% |
AI-Powered INCY Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 79.05%
79.05%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Incyte Corp. (INCY)
Tray Thomas
Sell
Principal Accounting Officer
INCY Nov 24, 2025
Avg Cost/Share
$103.00
Shares
600
Total Value
$61,800.00
Owned After
23,573
SEC Form 4
Tray Thomas
Sell
Principal Accounting Officer
INCY Nov 21, 2025
Avg Cost/Share
$102.00
Shares
169
Total Value
$17,238.00
Owned After
23,573
SEC Form 4
Denton Sheila A.
Sell
EVP & General Counsel
INCY Nov 17, 2025
Avg Cost/Share
$104.36
Shares
278
Total Value
$29,012.08
Owned After
26,569
SEC Form 4
Hoppenot Herve
Sell
Director
INCY Nov 10, 2025
Avg Cost/Share
$105.46
Shares
187,500
Total Value
$19,773,750.00
Owned After
329,646
SEC Form 4
Stein Steven H
Sell
EVP & Chief Medical Officer
INCY Nov 5, 2025
Avg Cost/Share
$102.20
Shares
5,233
Total Value
$534,812.60
Owned After
102,886
SEC Form 4
Denton Sheila A.
Sell
EVP & General Counsel
INCY Nov 4, 2025
Avg Cost/Share
$101.36
Shares
598
Total Value
$60,613.28
Owned After
26,569
SEC Form 4
Heeson Lee
Sell
EVP, Head of Incyte Intl
INCY Nov 3, 2025
Avg Cost/Share
$94.02
Shares
3,074
Total Value
$289,017.48
Owned After
29,241
SEC Form 4
Denton Sheila A.
Sell
EVP & General Counsel
INCY Oct 15, 2025
Avg Cost/Share
$85.13
Shares
277
Total Value
$23,581.01
Owned After
26,569
SEC Form 4
Denton Sheila A.
Sell
EVP & General Counsel
INCY Oct 3, 2025
Avg Cost/Share
$85.54
Shares
3,501
Total Value
$299,475.54
Owned After
26,569
SEC Form 4
Denton Sheila A.
Sell
EVP & General Counsel
INCY Oct 2, 2025
Avg Cost/Share
$87.65
Shares
599
Total Value
$52,502.35
Owned After
26,569
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tray Thomas | INCY | Principal Accounting Officer | Nov 24, 2025 | Sell | $103.00 | 600 | $61,800.00 | 23,573 | |
| Tray Thomas | INCY | Principal Accounting Officer | Nov 21, 2025 | Sell | $102.00 | 169 | $17,238.00 | 23,573 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Nov 17, 2025 | Sell | $104.36 | 278 | $29,012.08 | 26,569 | |
| Hoppenot Herve | INCY | Director | Nov 10, 2025 | Sell | $105.46 | 187,500 | $19,773,750.00 | 329,646 | |
| Stein Steven H | INCY | EVP & Chief Medical Officer | Nov 5, 2025 | Sell | $102.20 | 5,233 | $534,812.60 | 102,886 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Nov 4, 2025 | Sell | $101.36 | 598 | $60,613.28 | 26,569 | |
| Heeson Lee | INCY | EVP, Head of Incyte Intl | Nov 3, 2025 | Sell | $94.02 | 3,074 | $289,017.48 | 29,241 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Oct 15, 2025 | Sell | $85.13 | 277 | $23,581.01 | 26,569 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Oct 3, 2025 | Sell | $85.54 | 3,501 | $299,475.54 | 26,569 | |
| Denton Sheila A. | INCY | EVP & General Counsel | Oct 2, 2025 | Sell | $87.65 | 599 | $52,502.35 | 26,569 |
Latest Incyte Corp. News
INCY Breaking Stock News: Dive into INCY Ticker-Specific Updates for Smart Investing
Compare INCY vs Leading Stocks
See how INCY stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "INCY Incyte Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.